FDA Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), describe ...

Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when ...

Trenton M. Johnson is a seasoned project management leader with 27+ years of experience working in the biopharma industry ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...

Generative AI models aren’t perfect. Despite constant improvement, they still hallucinate and make mistakes. And for a ...

Pazdur, who currently leads the FDA's Oncology Center of Excellence (OCE) and has been with the agency for more than 25 years ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...